Company research
Equillium, Inc.
CIK 1746466Updated Sep 27, 2026
SecurityEQ · NASDAQ · equity
EQ price & chart
Loading TradingView…
NASDAQ:EQ on TradingView ↗About the company
Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways.
In the news
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 31,887,000Source | 25,604,000Source | 50,530,000Source | 78,421,000Source |
| Property, Plant and Equipment, NetUSD | 164,000Source | 262,000Source | 315,000Source | 391,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 30,277,000Source | 18,085,000Source | 23,216,000Source | 59,107,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 0Source | 3,735,000Source | 2,838,000Source |
| Assets, CurrentUSD | 31,038,000Source | 24,978,000Source | 49,349,000Source | 76,735,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 761,000Source | 2,403,000Source | 4,748,000Source | 2,874,000Source |
| Operating Lease, Right-of-Use AssetUSD | 658,000Source | 364,000Source | 796,000Source | 1,191,000Source |
| Other Assets, NoncurrentUSD | 27,000Source | — | 70,000Source | 104,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,290,000Source | 6,543,000Source | 27,957,000Source | 46,479,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 5,000Source | 3,000Source | 3,000Source | 3,000Source |
| Retained Earnings (Accumulated Deficit)USD | -216,205,000Source | -193,807,000Source | -185,740,000Source | -172,405,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 363,000Source | 781,000Source | 140,000Source | 76,000Source |
| Stockholders' Equity Attributable to ParentUSD | 28,597,000Source | 19,061,000Source | 22,573,000Source | 31,942,000Source |
| Additional Paid in Capital, Common StockUSD | 244,434,000Source | 212,084,000Source | 208,170,000Source | 204,268,000Source |
| Liabilities and EquityUSD | 31,887,000Source | 25,604,000Source | 50,530,000Source | 78,421,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,934,000Source | 6,356,000Source | 27,573,000Source | 32,038,000Source |
| Operating Lease, Liability, CurrentUSD | 363,000Source | 197,000Source | 440,000Source | 408,000Source |
| Accounts Payable, CurrentUSD | 755,000Source | 2,676,000Source | 4,707,000Source | 3,977,000Source |
| Operating Lease, Liability, NoncurrentUSD | 356,000Source | 187,000Source | 384,000Source | 824,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,816,000Source | 3,483,000Source | 6,697,000Source | 7,239,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 22,600,000Source | 40,900,000Source | 71,000,000Source |
| Deferred Revenue, CurrentUSD | — | — | 15,729,000Source | 14,700,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | — | 10,378,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | — | — | — | 5,714,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | 3,239,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -22,398,000Source | -8,067,000Source | -13,335,000Source | -62,428,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,322,000Source | 3,750,000Source | 3,997,000Source | 4,841,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | -3,735,000Source | 897,000Source | 2,838,000Source |
| Increase (Decrease) in Accounts PayableUSD | -1,937,000Source | -1,995,000Source | 723,000Source | 2,508,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -22,746,000Source | -19,026,000Source | -21,783,000Source | -8,733,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 4,464,000Source | 13,814,000Source | -4,762,000Source | 18,684,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 48,000Source | 85,000Source | 50,000Source | 279,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | 260,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 30,427,000Source | 164,000Source | -9,228,000Source | -1,215,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 12,192,000Source | -5,131,000Source | -35,891,000Source | 8,741,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 946,000Source | 847,000Source |
| Income Taxes Paid, NetUSD | 352,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,322,000Source | 3,750,000Source | 3,997,000Source | 4,841,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | 0Source | 180,000Source | 203,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 22,600,000Source | 40,900,000Source | 71,000,000Source |
| DepreciationUSD | 116,000Source | 137,000Source | 126,000Source | 118,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | 0Source | 0Source | — | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | 474,000Source | -794,000Source | -58,000Source | -260,000Source |
| Gain (Loss) on Disposition of AssetsUSD | -19,000Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -19,000Source | — | — | — |
| General and Administrative ExpenseUSD | 10,791,000Source | 11,936,000Source | 13,567,000Source | 17,239,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 361,000Source | 580,000Source | 0Source |
| Investment Income, InterestUSD | 833,000Source | 1,381,000Source | 2,334,000Source | 420,000Source |
| Net Income (Loss) Attributable to ParentUSD | -22,398,000Source | -8,067,000Source | -13,335,000Source | -62,428,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,767,000Source | -352,000Source |
| Operating ExpensesUSD | 23,634,000Source | 49,364,000Source | 50,606,000Source | 77,835,000Source |
| Operating Lease, ExpenseUSD | — | — | 500,000Source | 600,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -76,000Source | 281,000Source |
| Proceeds from Stock Options ExercisedUSD | 1,836,000Source | 4,000Source | — | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | 41,095,000Source | 36,084,000Source | 15,759,000Source |
| Operating Income (Loss)USD | -23,634,000Source | -8,269,000Source | -14,522,000Source | -62,076,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -76,000Source | 281,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -22,398,000Source | -7,706,000Source | -12,755,000Source | -62,428,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 361,000Source | 580,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -22,398,000Source | -8,067,000Source | -13,335,000Source | -62,428,000Source |
| Earnings Per Share, BasicUSD per share | -0.39Source | -0.23Source | -0.38Source | -1.85Source |
| Earnings Per Share, DilutedUSD per share | -0.39Source | -0.23Source | -0.38Source | -1.85Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 57,304,181Source | 35,357,641Source | 34,726,384Source | 33,727,945Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 57,304,181Source | 35,357,641Source | 34,726,384Source | 33,727,945Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | — | — | — | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | 118,000Source |
| General and Administrative ExpenseUSD | 10,791,000Source | 11,936,000Source | 13,567,000Source | 17,239,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | -22,398,000Source | -7,706,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -21,571,000Source | -6,008,000Source | -7,659,000Source | -60,403,000Source |
| Interest Expense, DebtUSD | — | — | 491,000Source | 1,053,000Source |
| Investment Income, InterestUSD | 833,000Source | 1,381,000Source | 2,334,000Source | 420,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,767,000Source | -352,000Source |
| Operating ExpensesUSD | 23,634,000Source | 49,364,000Source | 50,606,000Source | 77,835,000Source |
| Operating Lease, ExpenseUSD | — | — | 500,000Source | 600,000Source |
| Other IncomeUSD | 403,000Source | -818,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 37,039,000Source | 37,547,000Source |
Filing attachments
eq-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 eq-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA JOLLA, California, August 13, 2026 - Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator with a mission to develop hig…
Read attachment ↗eq-ex99_1.htm · 8-K · 2026-05-13
EX-99.1 2 eq-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter Equillium appoints Snehal Naik, Ph. D., as Chief Development Officer to lead clinical development and medical strategy Cash and cash equivalents expected to fund currently planned operations into 2029 LA JOLLA, California, May…
Read attachment ↗eq-ex99_1.htm · 8-K · 2026-03-25
EX-99.1 2 eq-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund operations into 2029 LA JOLLA, California, March 25, 2026 - Equillium, Inc. (Nasdaq: EQ), a clinical-stage …
Read attachment ↗